571189-03-2

Usage

Uses

Used in Pharmaceutical Industry:
Pyrido[2,3-d]pyriMidine-6-carboxylic acid, 8-cyclopentyl-2-[[5-[4-[(1,1-diMethylethoxy)carbonyl]-1-piperazinyl]-2-pyridinyl]aMino]-7,8-dihydro-5-Methyl-7-oxo-, ethyl ester is used as a pharmaceutical compound for its potential interactions with biological systems. The presence of various functional groups allows it to target specific receptors or enzymes, making it a promising candidate for the development of new drugs.
Used in Drug Delivery Systems:
As an ester prodrug, Pyrido[2,3-d]pyriMidine-6-carboxylic acid, 8-cyclopentyl-2-[[5-[4-[(1,1-diMethylethoxy)carbonyl]-1-piperazinyl]-2-pyridinyl]aMino]-7,8-dihydro-5-Methyl-7-oxo-, ethyl ester can be used in drug delivery systems to improve the bioavailability and pharmacokinetics of the active drug. The ester group can be hydrolyzed in the body, releasing the active compound and enhancing its absorption and distribution.
Further research is necessary to fully understand the properties and potential uses of Pyrido[2,3-d]pyriMidine-6-carboxylic acid, 8-cyclopentyl-2-[[5-[4-[(1,1-diMethylethoxy)carbonyl]-1-piperazinyl]-2-pyridinyl]aMino]-7,8-dihydro-5-Methyl-7-oxo-, ethyl ester, as well as to explore its efficacy and safety in various applications.

Upstream product

• 105-53-3 diethyl malonate 
• 1244949-62-9 C₁₁H₁₄ClN₃O 
• 571188-59-5 tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate 
• 39856-50-3 5-bromo2-nitropyridine 
• 571189-05-4 8-cyclopentyl-5-methyl-2-methylsulfanyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 
• 571189-16-7 4-(6-nitropyridin-3-yl)-piperazine-1-carboxylic acid tert-butyl ester 
• 362656-25-5 6-bromo-8-cyclopentyl-5-methyl-2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 775288-71-6 1-(6-nitropyridin-3-yl)piperazine 
• 571189-06-5 8-cyclopentyl-5-methyl-2-methanesulfinyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 

Downstream Products

• 1651214-74-2 4-[6-(6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-ylamino)pyridine-3-yl]piperazine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Palbociclib preparation method

The invention discloses a palbociclib preparation method, and relates to the field of organic synthesis. The method includes taking a compound I as a starting material; and preforming a five-step reaction to obtain palbociclib. The method has the advantages of simple operation, low requirement on equipment, easily-available raw materials, mild reaction conditions and high yield, so that the methodis suitable for industrial production.

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6

A pharmacological approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small molecule inhibitors has the potential to provide novel cancer therapies for clinical use. Achieving high levels of selectivity for Cdk4/6, versus other ATP-dependent kinases, presents a significant challenge. The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks. It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro. This selectivity profile is recapitulated in cells where the most selective inhibitors create a G1 block at concentrations up to 100-fold the IC50 for cell proliferation. On the basis of its selectivity profile and pharmacokinetic profile, compound 43 (PD 0332991) was identified as a drug candidate for the treatment of cancer.